key: cord-0690818-a2m1ea4u authors: Shulman, Rob; Montanari, Cecilia; Pinheiro, Inês; Longobardo, Alessia; Benhalm, Suzanne; Polhill, Sara; Singer, Mervyn; Bellingan, Geoff; Arulkumaran, Nishkantha title: Corticosteroids in adult respiratory distress syndrome – an inconvenient truth? date: 2021-09-01 journal: Int J Pharm Pract DOI: 10.1093/ijpp/riab053 sha: 86d095b79ab6a1041a950da02198495735f2fd4b doc_id: 690818 cord_uid: a2m1ea4u OBJECTIVES: Recent studies have demonstrated mortality benefits from corticosteroid use in COVID-19 patients requiring respiratory support. However, clinical practice may warrant the use of corticosteroids outside the context of a clinical trial. Such data are rarely, if ever, reported. We explored the use of corticosteroids for adult respiratory distress syndrome (ARDS) indications in patients with non-COVID ARDS. METHODS: We retrospectively studied patients with moderate-to-severe ARDS, admitted to our intensive care unit (ICU) between January 2018 and March 2020. KEY FINDINGS: Of the 91 patients with ARDS identified, 80% were treated with a corticosteroid during their ICU admission. Of these, 73 (82%) had corticosteroids administered for reasons other than ARDS. CONCLUSIONS: Corticosteroid use for non-ARDS indications is commonplace in ARDS patients in our ICU. The use of corticosteroids outside a randomisation process in randomised clinical trials may be more common than appreciated and needs to be routinely reported. Adult respiratory distress syndrome (ARDS) is a life-threatening condition characterised by poor oxygenation and 'stiff' lungs, with mortality of 32% and 45% for moderate and severe disease, respectively, [1] with a prevalence of 64.2-78.9 cases/100 000 person-years. [1] The benefit of corticosteroids in COVID-19 patients requiring respiratory support is clear in the light of recent evidence [2] and other trials are still underway. [3] Alongside other recent data supporting the use of corticosteroids in ARDS, [4] this intervention will undoubtedly be revisited in future trials. However, unlike other novel therapeutic interventions in COVID-19-like remdesovir and tocilizumab, corticosteroids are also often considered part of standard clinical care for a variety of non-ARDS indications. The aim of the work reported in this paper was to ascertain the use of corticosteroids for non-ARDS indications in patients with ARDS. A retrospective observational single-centre case series review was conducted using data from electronic healthcare records of patients admitted to the intensive care unit (ICU) at University College London Hospital between January 2018 and March 2020 (pre-COVID-19). Our main ICU is an adult, general unit with 35 beds, in a central London teaching hospital that gets tertiary referrals for patients with haemato-oncological malignancy. As data on corticosteroid use are collected as part of the routine service at our institution, our Research and Development link confirmed that ethical permission was not necessary. Our electronic health record was searched for mechanically ventilated patients with the phrase 'ARDS' in the notes. Their P/F ratios and hospital numbers were extracted into Microsoft Excel. The details of patients identified with moderate-to-severe ARDS, based on the Berlin definition, [5] were manually extracted on Excel for analysis by C.M. and I.P. The radiological scans were reviewed by S.P., C.M. and A.L. Details of any corticosteroid therapy were recorded, including indication, dosing and duration. Anonymised data were used for analysis. Continuous and categorical variables are reported as median (interquartile range) and n (%), respectively. The corticosteroid regimens were coded as per a classification previously described. [6] Here 'physiological' dose is classified as 'low' dose at the equivalent of prednisolone 7.5 mg daily, 'medium' dose 7.5-30 mg, 'high' dose 30-100 mg and 'very high' >100 mg. There were 4817 admissions to our Unit (some of whom were readmissions) during the data collection period. We identified 91 patients who fulfilled the criteria for moderate-to-severe ARDS ( Table 1 ). The median age was 53 (34-66) years, and 55% were male. Haemato-oncology patients accounted for the majority of this cohort (n = 46, 51%), while pulmonary infection accounted for the majority of ARDS aetiology (n = 64, 70%). All patients received invasive mechanical ventilation. Seventy percent of the 91 patients died in the ICU. Seventy-three (80%) of ARDS patients received corticosteroid treatment during their ICU stay. The time from ICU admission to first dosing was 1 (0-5) day and duration was 7 (3-17) days. Corticosteroid treatment included hydrocortisone for septic shock (n = 40, 54.8%), methylprednisolone/prednisolone for ARDS (n = 13, 17.7%) and methylprednisolone/prednisolone for Pneumocystis jirovecii pneumonia (PjP) (n = 8, 11%) as well as a range of corticosteroids for miscellaneous indications (n = 12, 16.4%). A total of 131 courses were administered, including one-off doses (Table 2) , with 20 patients receiving two courses, and 15 more than 2 courses. Many of the miscellaneous indications were for one-off doses of methylprednisolone or dexamethasone for haematological conditions. The regimens are described in Table 2 . The doses used were mostly 'very high' (including pulse) or 'high'. In ARDS there is an important disconnect between clinical trial patient selection and clinical practice. A majority of our patients with moderate-to-severe ARDS received corticosteroids, mostly for reasons other than ARDS, and multiple courses were common. Our study results need to be interpreted in the light of two important limitations. Firstly, our haemato-oncological subgroup is not representative or generalisable of the general ICU population. Secondly, there will be between-centre differences in prescribing practices, but the routine use of corticosteroids in patients with ARDS outside the context of a clinical trial is likely to be commonplace. The high number of miscellaneous steroid doses observed in our study highlights the importance of documenting the indication as part of the daily dynamic of medicine reconciliation. The high doses of corticosteroid used here for non-ARDS indications may have implications if corticosteroids are studied in ARDS or COVID-19. For example, a previous analysis reported that increased corticosteroid doses were linked to worsened mortality in sepsis. [7] Up to 25% of patients are excluded from clinical trials of ARDS because of underlying disease requiring long-or short-term concomitant corticosteroid use. [8] ARDS trials may also exclude patients with active cancer. Subsequent corticosteroid courses for other indications are often not reported. [9, 10] Similarly, some studies exploring the use of corticosteroids excluded patients who had received corticosteroids before admission [11] [12] [13] or who required corticosteroids acutely for any indication other than COVID-19 [11] or were expected to need corticosteroid [12] -though in this study 15% in the no corticosteroid group received a corticosteroid, which was allowed for new other indications. Indeed in the RECOVERY study, [14] 8% received corticosteroids in the usual care group. In our centre, most of the moderate-to-severe ARDS patients are treated with corticosteroids for reasons other than ARDS. Clinical trials investigating the utility of corticosteroids in COVID-19 and non-COVID-19 ARDS exclude patients who are treated with other corticosteroids before [4, 8, 9, 12, 13] or during ICU admission. [4, 8, 11, 12] It is therefore difficult to extrapolate the findings of these studies to routine clinical practice, which should have implications for the design of future clinical trials. R.S. and N.A. wrote the manuscript and conceived the study. C.M. and I.P. collected data and analysed results. A.L., S.B. and S.P. verified aspects of the data. G.B. and M.S. helped conceive the study and contributed to the writing of the manuscript. All had complete access to the data on request. This work was unfunded. All authors declare that there is no financial interest to declare in reference to this work. Acute Respiratory Distress Syndrome WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: protocol and statistical analysis plan Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial Acute respiratory distress syndrome: the Berlin Definition Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial Effects of methyl prednisolone in early ARDS Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Dexamethasone in hospitalized patients with Covid-19 All authors declare that there is no conflict of interest to declare in reference to this work.